Literature DB >> 19484191

Visual evoked potentials in succinate semialdehyde dehydrogenase (SSADH) deficiency.

G Di Rosa1, P Malaspina, P Blasi, C Dionisi-Vici, C Rizzo, G Tortorella, S R Crutchfield, K M Gibson.   

Abstract

In mammals, increased GABA in the central nervous system has been associated with abnormalities of visual evoked potentials (VEPs), predominantly manifested as increased latency of the major positive component P100. Accordingly, we hypothesized that patients with a defect in GABA metabolism, succinate semialdehyde dehydrogenase (SSADH) deficiency (in whom supraphysiological levels of GABA accumulate), would manifest VEP anomalies. We evaluated VEPs on two patients with confirmed SSADH deficiency. Whereas the P100 latencies and amplitudes for binocular VEP analyses were within normal ranges for both patients, the P100 latencies were markedly delayed for left eye (OS) (and right eye (OD), patient 1) and monocular OS (patient 2): 134-147 ms; normal <118 ms. We hypothesize that elevated GABA in ocular tissue of SSADH patients leads to a use-dependent downregulation of the major GABAergic receptor in eye, GABA(C), and that the VEP recordings' abnormalities, as evidenced by P100 latency and/or amplitude measurements, may be reflective of abnormalities within visual systems. This is a preliminary finding that may suggest the utility of performing VEP analysis in a larger sample of SSADH-deficient patients, and encourage a neurophysiological assessment of GABA(C) receptor function in Aldh5a1(-/-) mice to reveal new pathophysiological mechanisms of this rare disorder of GABA degradation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484191      PMCID: PMC2888988          DOI: 10.1007/s10545-009-1154-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

Review 1.  Magnetic resonance spectroscopy of neurotransmitters in human brain.

Authors:  Edward J Novotny; Robert K Fulbright; Phillip L Pearl; K Michael Gibson; Douglas L Rothman
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

2.  Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children.

Authors:  B Saletu; M Saletu; J Simeon; G Viamontes; T M Itil
Journal:  Biol Psychiatry       Date:  1975-06       Impact factor: 13.382

3.  Evaluation of cerebral function in newborn infants with fetal growth retardation.

Authors:  A Hrbek; K Iversen; T Olsson
Journal:  Adv Neurol       Date:  1982

4.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

5.  Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.

Authors:  G F Harding; J M Wild; K A Robertson; M C Lawden; T A Betts; C Barber; P M Barnes
Journal:  Epilepsia       Date:  2000-11       Impact factor: 5.864

6.  Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria).

Authors:  K Michael Gibson; Maneesh Gupta; Phillip L Pearl; Mendel Tuchman; L Gilbert Vezina; O Carter Snead; Leo M E Smit; Cornelis Jakobs
Journal:  Biol Psychiatry       Date:  2003-10-01       Impact factor: 13.382

Review 7.  Neurotransmitters in the cerebral cortex.

Authors:  E G Jones
Journal:  J Neurosurg       Date:  1986-08       Impact factor: 5.115

8.  Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation.

Authors:  G K Brown; C H Cromby; N J Manning; R J Pollitt
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

9.  Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency.

Authors:  Shinjiro Akaboshi; Boris M Hogema; Andrea Novelletto; Patrizia Malaspina; Gajja S Salomons; George D Maropoulos; Cornelis Jakobs; Markus Grompe; K Michael Gibson
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

10.  Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms.

Authors:  Paola Blasi; Pietro Pilo Boyl; Mario Ledda; Andrea Novelletto; K Michael Gibson; Cornelis Jakobs; Boris Hogema; Shinjiro Akaboshi; Fabrizio Loreni; Patrizia Malaspina
Journal:  Mol Genet Metab       Date:  2002-08       Impact factor: 4.797

View more
  4 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

2.  Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency.

Authors:  M Casarano; M G Alessandrì; G S Salomons; E Moretti; C Jakobs; K M Gibson; G Cioni; R Battini
Journal:  JIMD Rep       Date:  2011-09-06

3.  SSADH deficiency in an Italian family: a novel ALDH5A1 gene mutation affecting the succinic semialdehyde substrate binding site.

Authors:  Sara Leo; Concetta Capo; Bianca Maria Ciminelli; Federico Iacovelli; Giovanna Menduti; Silvia Funghini; Maria Alice Donati; Mattia Falconi; Luisa Rossi; Patrizia Malaspina
Journal:  Metab Brain Dis       Date:  2017-06-29       Impact factor: 3.584

4.  Succinic Semialdehyde Dehydrogenase Deficiency: In Vitro and In Silico Characterization of a Novel Pathogenic Missense Variant and Analysis of the Mutational Spectrum of ALDH5A1.

Authors:  Heiko Brennenstuhl; Miroslava Didiasova; Birgit Assmann; Mariarita Bertoldi; Gianluca Molla; Sabine Jung-Klawitter; Oya Kuseyri Hübschmann; Julian Schröter; Thomas Opladen; Ritva Tikkanen
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.